The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.
Read more...
Read More Details
Finally We wish PressBee provided you with enough information of ( Here's how much Ozempic and similar drugs have soared in popularity since 2018 )
Also on site :
- Trump Tariffs Leave UK Economy Uncertain
- This Startup Says It Can Clean Your Blood of Microplastics
- Private companies added 155,000 jobs in March, more than expected, ADP says